GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cell Source Inc (OTCPK:CLCS) » Definitions » Operating Margin %

Cell Source (Cell Source) Operating Margin % : 0.00% (As of Sep. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Cell Source Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Cell Source's Operating Income for the three months ended in Sep. 2023 was $-1.00 Mil. Cell Source's Revenue for the three months ended in Sep. 2023 was $0.00 Mil. Therefore, Cell Source's Operating Margin % for the quarter that ended in Sep. 2023 was 0.00%.

The historical rank and industry rank for Cell Source's Operating Margin % or its related term are showing as below:


CLCS's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -161.26
* Ranked among companies with meaningful Operating Margin % only.

Cell Source's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Cell Source's Operating Income for the three months ended in Sep. 2023 was $-1.00 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2023 was $-4.39 Mil.

Warning Sign:

Cell Source Inc has never been profitable in the past 3 years. It lost money every year.


Cell Source Operating Margin % Historical Data

The historical data trend for Cell Source's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cell Source Operating Margin % Chart

Cell Source Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cell Source Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cell Source's Operating Margin %

For the Biotechnology subindustry, Cell Source's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cell Source's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cell Source's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Cell Source's Operating Margin % falls into.



Cell Source Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Cell Source's Operating Margin % for the fiscal year that ended in Dec. 2022 is calculated as

Operating Margin %=Operating Income (A: Dec. 2022 ) / Revenue (A: Dec. 2022 )
=-4.175 / 0
= %

Cell Source's Operating Margin % for the quarter that ended in Sep. 2023 is calculated as

Operating Margin %=Operating Income (Q: Sep. 2023 ) / Revenue (Q: Sep. 2023 )
=-0.995 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cell Source  (OTCPK:CLCS) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Cell Source Operating Margin % Related Terms

Thank you for viewing the detailed overview of Cell Source's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cell Source (Cell Source) Business Description

Traded in Other Exchanges
N/A
Address
57 West 57th Street, Suite 400, New York, NY, USA, 10019
Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. Its other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched and mismatched organ transplantation.
Executives
George Verstraete director 341 LAKEWOOD DRIVE, BLOOMFIELD HILLS MI 48304
Darlene Soave director, 10 percent owner 341 LAKEWOOD DRIVE, BLOOMFIELD HILLS MI 48304
Yair Reisner 10 percent owner
Yoram Drucker director 31 DOV SADAN ST., JERUSALEM L3 97844
Dennis M Brown director 100 SAN MATEO DR, MENLO PARK CA 94025
Itamar Shimrat director, officer: CEO and CFO C/O CELL SOURCE, INC., 65 YIGAL ALON STREET, TEL AVIV L3 67433
David Zolty director C/O CELL SOURCE, INC., 65 YIGAL ALON STREET, TEL AVIV L3 67433
Benzion Abraham Friedman director, 10 percent owner C/O CELL SOURCE INC, 65 YIGALL ALON STREET, TEL AVIV L3 67433

Cell Source (Cell Source) Headlines